Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib in Relapsed or Refractory Leukemias
NCT00920140Phase 2Completed
- Sponsor
- GSK
- Start
- May 2011
- Primary completion
- Apr 2013
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of trametinib in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), sponsored by GSK. Started May 2011; status: completed.
02
Drugs
trametinib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)acute lymphoblastic leukemia (ALL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00920140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00920140.